SEC Form 4 · accession 0001493152-26-040207
PROVECTUS BIOPHARMACEUTICALS, INC. · PVCT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Edward Pershing
Officer — CEO · Director · 10% Owner
Period of report
Aug 26, 2026
Accepted (ET)
Aug 26, 2026 · 2:20 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0000315545
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 8% Unsecured Convertible Promissory NoteF6,F3,F4 | $2.862 | Aug 26, 2026 | M | — | D | Aug 26, 2025 | Aug 26, 2026 | Series D-1 Convertible Preferred Stock | 11,328 | — | D |
| Series D-1 Convertible Preferred StockF5,F1,F2 | — | Aug 26, 2026 | M | 11,328 | A | Aug 26, 2026 | — | Common Stock | 113,280 | 2,924,949 | D |
Explanation of responses
- F1Each share of Series D-1 Preferred Stock is convertible into 10 shares of the Issuer's common stock, par value $0.001 per share ("Common Stock").
- F2The Series D-1 Convertible Preferred Stock will automatically convert into Common Stock on December 31, 2028, unless earlier converted into Common Stock in accordance with the terms of the Certificate of Designation for the Series D-1 Convertible Preferred Stock.
- F3The Reporting Person could have voluntarily elected to convert the outstanding principal and interest of the 8% unsecured convertible promissory note (the "2025 Note") at any time while the 2025 Note was outstanding into shares of Series D-1 Convertible Preferred Stock at a price per share equal to $2.862. The outstanding principal and interest of the 2025 Note automatically converted into shares of Series D-1 Preferred Stock at a price per share equal to $2.862 on the date which is twelve months after the issue date of the 2025 Note. The 2025 Note was issued pursuant to the Issuer's 2025 Financing.
- F4On August 26, 2026, the 2025 Note converted into 11,328 shares of Series D-1 Preferred Stock.
- F5The amount reported reflects an adjustment to correct a typographical error in a previously filed Form 4. This adjustment does not reflect a transaction by the Reporting Person.
- F6The amount reported reflects an adjustment to correct a typographical error in a previously filed Form 4. This adjustment does not reflect a transaction by the Reporting Person.